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Abstract 
 
Osteochondral defects or injuries represent the most challenging entities to treat, especially when 
occur to young and active patients. For centuries, it has been recognized that such defects are 
almost impossible to treat. However, surgeons have never stopped the effort to develop reliable 
methods to restore articular cartilage and salvage the endangered joint function. Osteochondral 
 2 
allograft transplantation in human was first introduced by Eric Lexer in 1908. Since that era, 
several pioneers have been worked in the field of osteochondral allotransplantation, presenting and 
developing the basic research, the methodology and the surgical techniques. Herein we present in 
brief, the history and the early clinical results of osteochondral allograft transplantation in human.   
 
KeyWords: Osteochondra; transplantation; Allograft; history; 
 
Osteochondral defects or injuries represent the most challenging entities to treat, especially 
when occur to young and active patients. Such lesions involve the articular cartilage and the 
subchondral bone. For centuries, it has been recognized that such defects are almost impossible to 
treat. Back in 1743, William Hunter (1718-1783) stated that ³from Hippocrates down to the 
present age, ulcerated cartilage is a troublesome disease; when destroyed, it is not recovered´ [1, 
2] (Figure 1). Almost 100 years later, in 6LU-DPHV3DJHWZURWHµµThere are, I believe, no 
instances in which a lost portion of cartilage has been restored, or a wounded portion repaired, 
with new and well-formed permanent cartilage, in the human subject.¶¶ [3]. Since that era, 
tremendous effort has been made by orthopaedic surgeons to develop reliable methods to restore 
articular cartilage and salvage the endangered joint function.  
Both mechanical or biological methods have been developed for the treatment of the 
symptomatic osteochondral lesions.  Osteotomies, arthroplasty, micro-fractures, abrasion 
arthroscopy, mosaic-plasty and autologous chondrocyte transplantation techniques are currently 
used as treatment options. However, each method has limitations. Arthroplasty is generally not 
recommended for young active patients due to the risk of early failure or infection. Microfractures 
and abrasion arthroscopy leads to the formation of fibrocartilage or mixed hyaline and 
fibrocartilage.  Mosaic-plasty has the limitation of donor site morbidity and autologous 
chondrocyte transplantation demands two operations and is an expensive procedure. Even more 
importantly, all these methods are generally limited to defects less than 2-3 cm2 and 1-2 cm deep 
[4-6].  
On the other hand, fresh osteochondral allograft transplantation involves the transfer of 
size-matched allograft cartilage and subchondral bone into chondral or osteochondral defects. This 
method not only restores true type II hyaline cartilage but also directly address any associated bone 
defects. The nature of allograft chondral tissue is ideal for transplantation as it is avascular and 
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aneural tissue. Moreover, studies have shown that it is also relatively immunologically inactive 
and privileged, as the chondrocytes are embedded in the extracellular matrix [7].  
Henri Judet, first reported the implantation of osteochondral grafts in animals [8] but the 
clinical use of allograft joint transplants was first introduced by Lexer in 1908. Eric Lexer (Figure 
2) was born in Freiburg, Germany in 1867. He graduated medical school in Wurzburg in 1890 and 
he received his surgical training in Berlin. He was appointed Professor of surgery in Koninsberg, 
Jena, Freiburg and finally Munich in 1928. He died in 1937, leaving a tremendous amount of work 
in the fields of anatomy, bone infections and tissue transplantations. In the clinical setting, he was 
famous as a general and plastic surgeon [9].   
Lexer  published his early experience with ³MRLQWDOORWUDQVSODQWDWLRQ´E\ WKUHHGLIIHUHQW
methods; half joint replacement, both articular surfaces replacement and total joint transplantation, 
including joint capsule. The first case to present was a 38 years old male with proximal tibia 
sarcoma. 7KHDIIHFWHGSDUWRISDWLHQW¶VSUR[LPDOWLELDZDVVXUJLFDOO\UHPRYHGDQGUHSODFHGE\D 
proximal tibia osteochondral allograft. The allograft was taken, in a synchronous way, by a man 
whose leg was amputated due to gangrene. At the 8 month follow up, Lexer evaluated the outcome 
of this procedure as excellent. Interestingly, he described the procedures of allotransplantation of 
half joints and even total joints with good and fair results. All transplants were obtained by fresh 
amputated legs at the same day of surgery. However, he acknowledged that joint transplantation 
is not an easy procedure and that he was not able to promise successful and permanent results [10]. 
By 1925, Lexer had documented 34 hemi or whole knee allogenic implants in humans and reported 
a 50% success rate. [11] 
The following years a few more case reports [12, 13] had been published but the interest 
on osteochondral allograft transplantation remained limited, until the early 1970¶VZKHQ early 
reports of large series appeared. Volcov, from the Central Institute of Traumatology and 
Orthopaedics in Moscow, published in 1970 a series of 145 operations of joint allotransplantation. 
He reported four groups of operations; focal osteochondral transplantation, one joint surface with 
its supporting bone replacement, two joint surfaces replacement and whole joint complex 
replacement [14]. In most of the cases allografts harvested by persons that have died by injury or 
myocardial infraction, were preserved by freezing in -70 cC for 24 hours, followed by storage at -
30 oC.  Volcov reported good results in all fifteen cases of partial joint replacement and 60% good 
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results in patients with half joint replacement. In fifteen cases with total joint allotransplanations 
he reported inferior results eighteen months after transplantation [14].  
Approximately at the same period, Ottolenghi [15] and Parrish [16] published their 
experience with osteochondral allograft transplantation. In 1972, Carlos Ottolenghi presented the 
results of 62 patients with osteoarticular or metadiaphyseal bone allograft transplantation. From 
these patients 16 received osteoarticular transplant, mainly due to bone tumor resection. All grafts 
were obtained from dead people due to accidents or from amputated extremities of patients with 
congenital defects. The grafts were removed within 6 hours of death, under sterile conditions, and 
were stored in sterile boxes or bottles. Then, they were presented in freeze of -15 oC to -25 oC. All 
grafts were used within 6 months of harvesting. Before implantation grafts were thawed in a 
solution of penicillin for 30-60 mins. Overall 59% of patients had finally good results. 
Interestingly, Ottolenghi reported that in cases of osteoarticular allografts, results were good, (good 
range of joint motion and pain-free) even in cases that there were signs of graft absorption and 
necrosis [15].  
Similarly, in 1973, Frank Parrish, from Texas published the results of massive 
osteochondral allograft transplantation in patients with tumor of the end of long bone [16]. Overall, 
22 massive allografts were transplanted in 21 patients. Eleven patients had total and five partial 
replacements of different large joints, including the distal femur, the distal and proximal end of 
the tibia and the proximal end of humerus. The grafts were removed from adult donors, whose 
cause of death was trauma or heart disease. The osteochondral grafts were harvested within the 
first twelve to eighteen hours after the death of the donor, under usual sterile conditions. Cultures 
were taken and grafts were stored in -20 oC for at least three weeks. Twenty-four hours before 
transplantation, the grafts were removed from deep freeze and were submerged in solution 
containing neomycin and bacitracin and kept in ordinary refrigeration temperature. Parrish 
reported that at the latest follow-up, sixteen patients still had their limbs, three had amputations 
and one was lost to follow-up. The clinical results and functional status of patients  varied  
extensively but he did mention that these results appeared to justify continuation of the 
osteochondral allograft transplantation procedure [16].  
The revived interest in osteochondral allograft transplantation that was observed in the late 
¶VDQGHDUO\¶VFDQEHDWWULEXWHGWRWKHbetter understanding of the grafts immunogenicity and 
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the optimal methods of preservation and storage.  Early experimental studies by Paul Curtiss [17-
19], and Herndon [20], effectively showed that freezing the cadaveric bony parts reduce 
immunological activity and thus reduce the rejection rate. Fred Langer and co-workers from 
Canada, have also shown that a blocking antibody was produced by the temperature reduction 
[21]. Also Langer and Gross, in 1974 concluded that chondrocytes are relatively 
immunoprivileged, as the surrounding matrix protects them from the immunocompetent cells 
assault [7] . On the other hand, also early studies have shown that preservation of the grafts by 
freezing cause chondrocyte death in 90% to 50%, depending on the freezing methods  [22]. Thus, 
different centers, mainly in North America and elsewhere have started to use different methods of 
cryopreservation of osteochondral allografts with mixed results. Generally, the standards for grafts 
cryopreservation have been established at either -70 to -80 oC for frozen grafts or 4 o&IRU³IUHVK´
grafts. Additionally, 5LQJHU¶V ODFWDWH RU cryoporotectants, such as ethylene glycol, dimethyl 
sulfoxide or glycerol were used during the freezing process to minimize chondrocyte death. At the 
same time the first bone banks were developed [23] and relatively large series with the first results 
in humans have started to be published.  
Allan Gross has been a pioneer in the use of osteochondral transplantation for traumatic 
defects of the hip and knee. Gross and co-workers published in 1975 the first results of 
allotransplantation of osteochondral allografts in the treatment of knee osteoarthritis in eight 
patients [24]. Grafts were harvested within 24 hours of WKH GRQRU¶V GHDWK DQG ZHUH VWRUHG LQ
Normasol M with Gentamycin and cephaloridine at 4 oC until implantation. They reported the 
early follow-up from 6 months to 2 years post-surgery. Results were very encouraging, as there 
was no rejection, all patients were fully ambulatory and developed good functional range of 
movement. In one patient they performed histological testing that revealed cartilage viability at 14 
months [24].  
Few years later, the same group published the results of 110 osteochondral transplants in 
patients with deficits due to degeneration, trauma, and neoplasm, mainly involving the knee joint 
[23]. They have used fresh grafts stored at 4 oC in Normosol M with cefazolin and gentamycin or 
frozen grafts stored at -70 oC. Fresh grafts were used within 24 hours from harvesting. They 
analyzed results of small fragment grafts (mainly fresh) and large fragment grafts (fresh or frozen). 
Overall, they reported 78 small fragment grafts and 32 large fragment grafts. Interestingly they 
reported that graft success depended more on the fate of bone than that of the cartilage, meaning 
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that if the bony part of the graft was compressed or fragmented, instability and malalignment 
occurred and the donor cartilage could be replaced by host fibrocartilage. Grafts with better results 
were those done for plateau fractures, trauma and giant cell tumors [23].  
Beaver and co-workers, from the same center in Canada, reported the survivorship analysis 
of fresh osteochondral allografts of the knee in 98 patients ( 99 knees) [25]. In this series, donors 
were chosen to be less than 30 years old, to maximize cartilage quality. Grafts were harvested 
within 24 hours of death and when possible within 12 hours. Storage was made in antibiotic 
containing sterLOH5LQJHU¶VVROXWLRQDQG WHPSHUDWXUHRI oC. The mean follow-up time was 68 
months. Survival analysis showed that at five, ten and fourteen years after transplantation, the 
clinical success rate was 75%, 64% and 64% respectively. Authors analyzed that clinical success 
depended more upon biomechanical factors than upon graft rejection. Additionally, they stated 
that for the long term survival of the fresh allograft, there are three perquisites; firstly the 
transplanted chondrocytes must remain viable. Secondly chondrocytes must continue to produce 
sufficient proteoglycan and collagen and thirdly the subchondral bone must be preserved [25].  
Marvin Meyers and co-workers from Texas, presented their experience with fresh 
osteochondral allograft transplantation in 20 (21 hips) relatively young patients suffering from 
segmental collapse, in osteonecrosis of the hip [26].  Donors were 16-40 years old and the whole 
femoral head graft was harvested within 12 hours from death. Allografts were placed in antibiotics 
FRQWDLQLQJ5LQJHU¶VVROXWLRQDQGVWRUHGLQoC for up to 72 hours. Authors reported that 15 of the 
21 hips had successful results. Nine patients had more than 18 months follow-up, five more than 
two years and two five years follow-up. The overall success rate was 71%. Patients with steroid 
induced avascular necrosis did worst [26].  
John Garrett, also published the early results of osteochondral transplantation in 24 
patients, suffering from osteochondral defects of a femoral condyle [27]. He has used fresh 
allografts from young donors. Transplantation was done within 12 hours from harvesting. The 
follow-up time was between 1 and 4 years. Garrett reported good results, as all patients improved 
at the latest follow-up. He was able to arthroscopically evaluate 11 allografts and concluded that 
in all cases graft appeared viable [27].  
These are some of the earliest follow-up studies, demonstrating good to excellent clinical 
results of osteochondral allograft transplantation, mainly in the fields of hip and knee surgery. 
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Following these encouraging results research efforts have been intensified and better methods of 
allograft harvesting, handling, preservation and implantation have been presented [28-30]. Use of 
osteochondral allografts has been expanded to almost all the fields of orthopaedic surgery, 
including the patellofemoral joint [31], foot and ankle [32, 33] and shoulder and elbow [34-36] 
surgery.  Long follow-up studies have recently been published confirming excellent long-term 
graft survival [37-39].  
There is no dough that as research continues in several areas, results will further be 
improved. Surgical techniques will be simplified and better tissue banking networking will 
allows  a greater number of osteochondral allografts to become  available for patients. Thus the 
³PLUDFOH´SHUIRUPHGE\6DLQWV&RVPDVDQG'DPLDQDWWKHVL[WKFHQWXU\$'[40]NQRZQDV³7KH
PLUDFOHRIWKHEODFNOHJ´ (Figure 3),  will come as closer to reality as ever.  
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Figure 1: William Hunter (1718ʹ1783). 
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Figure 2: Dr. Erich Lexer (1867ʹ1937) 
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Figure 3: Spanish altarpiece of Saints Cosmas and Damnian, performing  the miracle of 
transplanting a leg (the miracle of black leg). 
 
 
